Sagimet Biosciences (SGMT) Assets Average (2023 - 2026)

Sagimet Biosciences' Assets Average history runs 4 years deep, the most recent figure standing at $112.1 million for Q1 2026.

• On a quarterly basis, Assets Average fell 26.82% year-over-year to $112.1 million in Q1 2026; TTM through Mar 2026 was $112.1 million, a 26.82% decrease from a year earlier, with the FY2025 full-year figure at $138.4 million, up 7.69% from the prior year.
• Assets Average retreated to $112.1 million in Q1 2026 per SGMT's latest filing, from $122.4 million in the prior quarter.
• Across five years, Assets Average topped out at $191.8 million in Q2 2024 and bottomed at $62.2 million in Q3 2023.
• The 4-year median for Assets Average is $141.8 million (2025), against an average of $137.4 million.
• Across the five-year window, Assets Average jumped 192.39% in 2024 and decreased 26.93% in 2025, its largest moves.
• Year by year, Assets Average stood at $99.8 million in 2023, then jumped by 67.82% to $167.5 million in 2024, then fell by 26.91% to $122.4 million in 2025, then declined by 8.43% to $112.1 million in 2026.
• Per Business Quant, the three latest SGMT Assets Average figures stand at $112.1 million (Q1 2026), $122.4 million (Q4 2025), and $132.9 million (Q3 2025).